Core Viewpoint - The ongoing controversy regarding the content of recombinant collagen products from Giant Bio (02367.HK) remains unresolved, with the company not directly addressing anonymous criticisms from testing agencies [1][2]. Group 1: Company Response and Actions - On June 23, Giant Bio acknowledged the limitations of its current quality standards and announced a technical improvement plan in response to market discussions about its recombinant collagen products [2][3]. - The company has conducted a comprehensive self-inspection of its production, testing, and packaging processes, and is validating different testing methods to address recent controversies [3]. - Giant Bio plans to collaborate with research institutions to optimize qualitative and quantitative testing methods for cosmetic recombinant collagen, and will gradually disclose key technical parameters and quality control data [3][4]. Group 2: Industry Standards and Market Impact - Giant Bio has been a pioneer in the recombinant collagen field since applying for a patent in 2001, and it adheres to various industry standards that have been implemented from 2021 to 2025 [3]. - The company's recent statement led to a rebound in its stock price, although it has experienced significant volatility over the past month, dropping from a high of 85.14 HKD on May 20 to 54.6 HKD by June 24 [4]. - The company's market capitalization has decreased by nearly 30 billion HKD from its previous peak, now standing at 584.7 billion HKD [5].
市值蒸发近300亿港元，巨子生物：优化检测方法并公开数据